Australian Biotechnology News

clinical trials

  • Bionomics anxiety drug could be more effective than valium 31/08/2010 00:16:00

    Study results show BNC210 more effective in treating stressed rats with Phase Ib trials scheduled for later this year
    Adelaide biotech Bionomics has presented the results of preclinical and clinical data for its anti-anxiety compound BNC210, demonstrating that the drug is more effective in treating stressed rats than the current market leader valium (Diazapem).
  • Clinuvel identifies potential new target for Scenesse 25/08/2010 18:59:00

    Clinuvel plans to start clinical trials on sufferers of skin pigmentation disorder vitiligo
    Melbourne biotech Clinuvel announced today that it plans to conduct clinical trials of its UV protection drug Scenesse as a treatment for the skin pigmentation disorder vitiligo.
  • Feature: Xenotransplantation offers hope to diabetes sufferers 16/08/2010 15:33:00

    A xenotransplantation technology using insulin producing cells from pigs offers new hope for diabetes sufferers.
    Back when Living Cell Technologies's (LCT) current Medical Director and Founder, Professor Bob Elliott, was working in his Auckland clinic, he decided that the treatments available for patients with Type I diabetes simply weren't good enough.
  • LCT to extend NZ diabetes trial 04/08/2010 18:54:00

    Early indications positive for treatment against Type 1 diabetes
    Xenotransplantation specialists Living Cell Technologies (LCT) announced today that promising results from a Phase II clinical trial of its cell implant Diabecell in diabetes patients in New Zealand had prompted the country’s health regulator to approve the addition of four more patients.
  • Patrys to start clinical trials on melanoma patients 02/08/2010 16:25:00

    PAT-SM6 human antibody to be trailed on 10 Australian melanoma sufferers
    Melbounre biotech Patrys announced today that the Royal Adelaide Hospital has approved a clinical trial evaluating its PAT-SM6 natural human antibody as a treatment for melanoma.
  • Australian Life Scientist July/August edition out now 28/07/2010 15:36:00

    The Human Proteome Organisation (HPUO) 2010 World Congress and the Human Proteome Project feature in this issue, along with proteomics, synthetic biology, genetics and genomics, and next generation genome sequencing.
    The July/August edition of Australian Life Scientist is out now. The issue takes an in-depth look at the happenings at the upcoming Human Proteome Organisation (HPUO) 2010 World Congress, which will host the launch of the long awaited Human Proteome Project.
  • Hurdles remain for Botox as a migraine treatment 28/07/2010 14:28:00

    Clincal trial setback while high costs point to reimbursement restrictions
    Botox was approved in the UK this month for the treatment of migraines, however, the high costs of the cosmetic treatment as well as lingering safety concerns may restrict its ability to penetrate this new market.
  • Biota Holdings targeting asthma market with anti-viral drug 27/07/2010 18:45:00

    US clinical trial of anti-viral BTA798 to treat human rhinovirus to coincide with onset of northern hemisphere flu season.
    Biota Holdings today commenced a 400-member trial in the US of its anti-viral drug BTA798 on sufferers of asthma who present with cold symptoms.
  • Ecstasy study gives hope to PTSD sufferers 21/07/2010 00:02:00

    MDMA shown to be far more effective than SSRIs and therapy
    US researchers have published the results of the first ever clinical trial examining the effectiveness of MDMA in treating sufferers of post traumatic stress disorder (PTSD).
  • New study on bowel cancer treatment 02/06/2010 14:05:00

    Australian researchers identify two non-chemo alternatives for bowel cancer treatment
    The results of an Australian clinical trial assessing two new treatment approaches for bowel cancer patients unable to withstand chemotherapy were published today in the prestigious medical journal, the Journal of Clinical Oncology.
  • Market Spotlight: QRxPharma on the up 14/04/2010 11:04:00

    QRxPharma's dual-opioid, MoxDuo, completes first of two pivotal Phase III trials, on track for NDA by end of 2010.
    QRxPharma is another step closer to bringing its immediate release dual-opioid pain therapy, MoxDuoIR, to the market with the completion of one of two pivotal Phase III clinical trials held in the United States.
  • Breast cancer linked to stem cells 12/04/2010 14:56:00

    The mechanism linking breast cancer to stem cells has been uncovered, which could lead to new cancer treatments.
    The mechanism linking breast cancer to stem cells has been uncovered, which could lead to new cancer treatments.
  • Bias in scientific publishing rife 01/04/2010 11:32:00

    A reluctance to publish negative results is leading to a troubling bias in scientific journals.
    A reluctance to publish negative results is leading to a troubling bias in scientific journals.
  • Clinuvel to commence trial of afamelanotide in the US 30/03/2010 12:01:00

    Phase II trial to test effectiveness of afamelanotide in treating erythropoietic protoporphyria.
    Phase II trial to test effectiveness of afamelanotide in treating erythropoietic protoporphyria.
  • Living Cell Technology to begin phase II diabetes trial 30/03/2010 11:41:00

    New clinical trial for type I diabetes treatment using xenotransplantation of pig cells to begin in New Zealand.
    New clinical trial for type I diabetes treatment using xenotransplantation of pig cells to begin in New Zealand.
More >
Syndicate content
 
Jobs